肠道菌群失调对肝硬化的影响

李云鹏; 王新红; 张德凯

doi:10.3969/j.issn.1001-5256.2019.04.040

肠道菌群失调对肝硬化的影响

DOI: 10.3969/j.issn.1001-5256.2019.04.040

哈尔滨医科大学附属第二医院消化内科

基金项目:

哈医大海外人才引进专项基金；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1411
- HTML全文浏览量: 50
- PDF下载量: 287
- 被引次数: 0
出版历程
- 出版日期: 2019-04-20

Influence of intestinal dysbacteriosis on liver cirrhosis

Department of Gastroenterology, The Second Affiliated Hospital of Harbin Medical University

Research funding:

摘要

摘要: 肝硬化是由一种或多种原因引起的、以肝组织弥漫性纤维化、假小叶和再生结节为组织学特征的进行性慢性肝病,一旦进入失代偿期,肝脏和其他多脏器功能受损,几乎无法恢复和逆转。介绍了Toll样受体识别肠道菌群变化从而影响肝硬化及其并发症发生发展的过程。简述了胆汁酸调控肠道菌群对于肝硬化的保护作用。回顾了治疗肠道菌群失调后延缓肝硬化的进展。认为未来针对肠道菌群失调的治疗将会是肝硬化治疗的主要方向。
- 肝硬化 /
- 肠杆菌科 /
- 细菌移位 /
- 综述
Abstract: Liver cirrhosis is a progressive chronic liver disease due to one or more causes, with diffuse fibrosis in liver tissue, pseudolobules, and regenerative nodules as major histological features. Once liver cirrhosis enters the decompensated stage, the liver and several other organs are injured, which can hardly be recovered or reversed. This article introduces the process of Toll-like receptors in recognizing the changes in intestinal flora and the influence of this process on the development and progression of liver cirrhosis, as well as the protective effect of bile acid against liver cirrhosis by regulating intestinal flora. This article also reviews the advances in delaying liver cirrhosis after the treatment of intestinal dysbacteriosis and points out that the treatment of intestinal dysbacteriosis may become the major direction of liver cirrhosis treatment in future.
- liver cirrhosis /
- enterobacteriaceae /
- bacterial translocation /
- review

HTML全文

参考文献(33)

[1]BRENNER DA, PAIK YH, SCHNABL B. Role of gut microbiota in liver disease[J]. J Clin Gastroenterol, 2015, 49 (Suppl 1) :s25-s27.

[2]ZHANG Y, FENG Y, CAO B, et al. The effect of small intestinal bacterial overgrowth on minimal hepatic encephalopathy in patients with cirrhosis[J]. Arch Med Sci, 2016, 12 (3) :592-596.

[3]PURI P, SANYAL AJ. The intestinal microbiome in nonalcoholic fatty liver disease[J]. Clin Liver Dis, 2018, 22 (1) :121-132.

[4]BORRELLI A, BONELLI P, TUCCILLO FM, et al. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma:Current and innovative therapeutic approaches[J]. Redox Biol, 2018, 15:467-479.

[5]SHAH A, SHANAHAN E, MACDONALD GA, et al. Systematic review and meta-analysis:Prevalence of small intestinal bacterial overgrowth in chronic liver disease[J]. Semin Liver Dis, 2017, 37 (4) :388-400.

[6]KONG L, LU Y, ZHANG S, et al. Role of nutrition, gene polymorphism, and gut microbiota in non-alcoholic fatty liver disease[J]. Discov Med, 2017, 24 (131) :95-106.

[7]LI W, ZHANGK, YANG H. Pectin alleviates high fat (lard) Diet-induced nonalcoholic fatty liver disease in mice:Possible role of short-chain fatty acids and gut microbiota regulated by pectin[J]. J Agric Food Chem, 2018, 66 (30) :8015-8025.

[8]ALTAMIRANO-BARRERA A, URIBE M, CHAVEZ-TAPIA NC, et al. The role of the gut microbiota in the pathology and prevention of liver disease[J]. J Nutr Biochem, 2018, 60:1-8.

[9]ZHU L, BAKER RD, BAKER SS. Gut microbiome and nonalcoholic fatty liver diseases[J]. Pediatr Res, 2015, 77 (1-2) :245-251.

[10]CAHOVA M, BRATOVA M, WOHL P. Parenteral nutrition-associated liver disease:The tole of the gut microbiota[J]. Nutrients, 2017, 9 (9) :987.

[11]WIEST R, LAWSON M, GEUKING M. Pathological bacterial translocation in liver cirrhosis[J]. J Hepatol, 2014, 60 (1) :197-209.

[12]DAVIS BC, BAJAJ JS. The human gut microbiome in liver diseases[J]. Semin Liver Dis, 2017, 37 (2) :128-140.

[13]TILG H, CANI PD, MAYER EA. Gut microbiome and liver diseases[J]. Gut, 2016, 65 (12) :2035-2044.

[14]WEN Z, JI X, TANG J, et al. Positive feedback regulation between transglutaminase 2 and Toll-Like receptor 4 signaling in hepatic stellate cells correlates with liver fibrosis post schistosoma japonicum Infection[J]. Front Immunol, 2017, 8:1808.

[15]YAN C, LI B, FAN F, et al. The roles of Toll-like receptor 4 in the pathogenesis of pathogen-associated biliary fibrosis caused by Clonorchis sinensis[J]. Sci Rep, 2017, 7 (1) :3909.

[16]KANG HH, KIM IK, LEE HI, et al. Chronic intermittent hypoxia induces liver fibrosis in mice with diet-induced obesity via TLR4/MyD88/MAPK/NF-kB signaling pathways[J]. Biochem Biophys Res Commun, 2017, 490 (2) :349-355.

[17]KUMAR S, WANG J, SHANMUKHAPPA SK, et al. Toll-Like receptor 4-independent carbon tetrachloride-induced fibrosis and lipopolysaccharide-induced acute liver injury in mice:role of hepatic stellate cells[J]. Am J Pathol, 2017, 187 (6) :1356-1367.

[18]GOMEZ-HURTADO I, SUCH J, FRANCES R. Microbiome and bacterial translocation in cirrhosis[J]. Gastroenterol Hepatol, 2016, 39 (10) :687-696.

[19]BAJAJ JS, BETRAPALLY NS, GILLEVET PM. Decompensated cirrhosis and microbiome interpretation[J]. Nature, 2015, 525 (7569) :e1-e2.

[20]SINGH A, CRESCI GA, KIRBY DF. Proton pump inhibitors:Risks and rewards and emerging consequences to the gut microbiome[J]. Nutr Clin Pract, 2018, 33 (5) :614-624.

[21]Chinese Society of Hepatology, Chinese Medical Association.Guidelines on the management of hepatic encephalopathy in cirrhosis[J/CD]. Chin J Liver Dis:Electronic Edition, 2018, 10 (4) :17-32. (in Chinese) 中华医学会肝病学分会.肝硬化肝性脑病诊疗指南[J/CD].中国肝脏病杂志:电子版, 2018, 10 (4) :17-32.

[22]YILDIZ S, DOGAN I·, DOGRUMAN-Al F, et al. Association of enteric protist blastocystis spp and gut microbiota with hepatic encephalopathy[J]. J Gastrointestin Liver Dis, 2016, 25 (4) :489-497.

[23]LACHAR J, BAJAJ JS. Changes in the microbiome in cirrhosis and relationship to complications:Hepatic encephalopathy, spontaneous bacterial peritonitis, and sepsis[J]. Semin Liver Dis, 2016, 36 (4) :327-330.

[24]ACHARYA C, BAJAJ JS. Gut microbiota and complications of liver disease[J]. Gastroenterol Clin North Am, 2017, 46 (1) :155-169.

[25]SANTIAGO A, POZUELO M, POCA M, et al. Alteration of the serum microbiome composition in cirrhotic patients with ascites[J]. Sci Rep, 2016, 6:25001.

[26]AITBAEV KA, MURKAMILOV IT, FOMIN VV. Liver diseases:The pathogenetic role of the gut microbiome and the potential of treatment for its modulation[J]. Ter Arkh, 2017, 89 (8) :120-128.

[27]ZAPATER P, GONZALEZ-NAVAGAS JM, SUCH J, et al. Immunomodulating effects of antibiotics used in the prophylaxis of bacterial infections in advanced cirrhosis[J]. World J Gastroenterol, 2015, 21 (41) :11493-11501.

[28]PONZIANI FR, GERARDI V, PECERE S, et al. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications[J]. World J Gastroenterol, 2015, 21 (43) :12322-12333.

[29]GOMEZ-HURTADO I, GIMENEZ P, GARCIA I, et al. Norfloxacin is more effective than Rifaximin in avoiding bacterial translocation in an animal model of cirrhosis[J]. Liver Int, 2018, 38 (2) :295-302.

[30]SARANGI AN, GOEL A, SINGH A, et al. Faecal bacterial microbiota in patients with cirrhosis and the effect of lactulose administration[J]. BMC Gastroenterol, 2017, 17 (1) :125.

[31]SUN YP, GUO XX. Clinical effect of probiotics in treatment of liver cirrhosis:A meta-analysis[J]. J Clin Hepatol, 2018, 34 (1) :73-79. (in Chinese) 孙元培, 郭晓霞.微生态制剂治疗肝硬化的Meta分析[J].临床肝胆病杂志, 2018, 34 (1) :73-79.

[32]LIU J, FU UY, ZHANG H, et al. The hepatoprotective effect of the probiotic Clostridium butyricum against carbon tetrachloride-induced acute liver damage in mice[J]. Food Funct, 2017, 8 (11) :4042-4052.

[33]LAVEKAR AS, RAJE DV, MANOHAR T, et al. Role of probiotics in the treatment of nonalcoholic fatty liver disease:A meta-analysis[J]. Euroasian J Hepatogastroenterol, 2017, 7 (2) :130-137.

施引文献

资源附件(0)

访问统计